Exhibit 99.1 NeoGenomics Reports Third Quarter 2024 Results Adjusted EBITDA Improves 305%; Fifth Consecutive Quarter of Positive Adjusted EBITDA; Increasing FY Guidance to $37-$40 Million Fort Myers, Florida (November 5, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024. | --- | |-----------------------------------------------------------------------------------| | | | Third ...